Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis

Yin P Hung1, Julio A Diaz-Perez2, Gregory M Cote3

  • 1Departments of Pathology.

Insights

Dedifferentiated chordoma, a rare subtype, features high-grade sarcoma alongside conventional chordoma. Genetic analysis reveals TP53 mutations in the dedifferentiated component, impacting tumor suppressor pathways and prognosis.

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Background:

  • Dedifferentiated chordoma is a rare, aggressive subtype of chordoma.
  • It is characterized by the presence of a high-grade sarcoma component adjacent to conventional chordoma.
  • Understanding its clinicopathologic and molecular features is crucial for diagnosis and treatment.

Purpose of the Study:

  • To characterize the clinicopathologic features of dedifferentiated chordoma.
  • To investigate the molecular alterations, including genetic mutations, in dedifferentiated chordoma.
  • To analyze patient outcomes and survival data for this rare tumor subtype.

Main Methods:

  • Retrospective review of a series of dedifferentiated chordoma cases.
  • Histopathological and immunohistochemical analysis (cytokeratin, brachyury, INI1).
  • Next-generation sequencing (NGS) for genetic mutation profiling.
  • Comprehensive literature review of previously reported cases.

Main Results:

  • Dedifferentiated chordoma occurs in diverse anatomical sites (sacrum, skull base, spine, mediastinum, lung metastasis).
  • The dedifferentiated component shows loss of cytokeratin and brachyury expression.
  • Next-generation sequencing identified tumor suppressor mutations, notably TP53 mutations in 3/4 analyzed cases.
  • High rates of metastasis and mortality were observed, with a median overall survival of 20 months.

Conclusions:

  • Dedifferentiated chordoma presents de novo, as recurrence, or metastasis, often years after initial diagnosis.
  • Loss of brachyury and cytokeratin, along with TP53 mutations, are key features of the dedifferentiated component.
  • Tumor suppressor dysregulation likely plays a significant role in chordoma dedifferentiation and aggressive behavior.

Related Concept Videos